We provide evidence supporting PART+LB as a distinct group presenting with dementia severity progression intermediate between PART w/o LB and AD with and without LB pathology across multiple cognitive domains, patterns of brain atrophy, and with a topographical pattern of tau and alpha‐synuclein pathology that precedes that of ADNC. This evidence concerns the gene MAPT and Alzheimer disease.